BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Menarini Silicon Biosystems Publishes DETECT III Trial Results on HER2 Testing in Circulating Tumor Cells with CELLSEARCH

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of the fina...

January 10, 2024 | News

GC Cell Initiates Phase 1 Trials for AB-201 Cancer Treatment with Lunit AI Platform

GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) a...

January 09, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

January 09, 2024 | News

Caliway's CBL-514 IND for Dercum's Disease Phase 2 Study Accepted by FDA

Dercum's disease is a rare disease characterized by the growth of painful lipomas. The pain can be severe, chronic (> 3 months) and often disabling. So ...

January 09, 2024 | News

Suvoda Achieves 30% Growth in 2023 with Successful Platform and Product Adoption

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...

January 08, 2024 | News

Akeso's Cadonilimab Granted NMPA Acceptance for First-Line Gastric Cancer Treatment.

This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...

January 08, 2024 | News

Belief BioMed Completes First Dosing in Hemophilia A Trial

BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...

January 04, 2024 | News

Sciwind Biosciences Reports Positive Phase 3 Results for Ecnoglutide in Chinese Type 2 Diabetes Trial

Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, ...

January 03, 2024 | News

MediLink Therapeutics Partners with Roche for Oncology Antibody Drug Conjugate

Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's...

January 03, 2024 | News

NeuroBo Pharma Seeks FDA Approval for Obesity Treatment Trial

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, anno...

January 02, 2024 | News

Alcresta Therapeutics Receives FDA Clearance for RELiZORB® Cartridge

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, announced 510(...

January 02, 2024 | News

Mundipharma Greenlights European Approval for REZZAYO® in Treating Adult Invasive Candidiasis

The approval is based on the positive results of the pivotal Phase III ReSTORE clinical trial and is supported by STRIVE's Phase II clinical trials and a...

January 01, 2024 | News

Elpiscience, Astellas Ink Deal for Novel Bispecific Macrophage Engager

The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up ...

January 01, 2024 | News

TiumBio Raises KRW 38.5B for Upcoming Clinical Data

The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. Data read-outs from a Phase 2 trial of merigolix...

January 01, 2024 | News

Stay Connected